Leadership

Dr. Kumar has been an investor, founder, director and CEO of several technology enterprises, both public and private. As CEO, he took CombiMatrix Corporation public and ran it for a decade while listed on the NASDAQ Global Market. He has worked in venture capital with OAK Investment Partners, and has been an advisor to investment funds, venture capital firms, and Fortune 500 companies. He was on the Board of Directors of Acacia Research Corporation from 2002-2008. Dr. Kumar is currently Chairman and CEO of Anixa Biosciences and he sits on the Board of other public and private companies. He has served on the Board of the American Cancer Society since 2016. He received his AB in Chemistry from Occidental College. After graduate studies at Stanford University and Caltech, he received his Ph.D. from Caltech and followed that with a post-doctoral fellowship at Harvard.

Mr. Catelani is a seasoned executive with over 30 years of finance and operations management experience. He currently serves as President, Chief Operating Officer & Chief Financial Officer of Anixa Biosciences. Previously, Mr. Catelani cofounded Tacere Therapeutics, Inc., a privately held biotech company, and served as its Chairman, President & Chief Financial Officer until its sale. Prior to Tacere, Mr. Catelani served on the Board of Directors and was the Chief Financial Officer of Benitec Biopharma Limited, an Australian Stock Exchange-listed biotech company. Mr. Catelani was Vice President and Chief Financial Officer at Axon Instruments, a leading designer and manufacturer of instrumentation and software systems for biotechnology and diagnostics research. Axon was a U.S. corporation publicly traded on the Australian Stock Exchange. Previously, he was the Vice President of Finance for Media Arts Group, Inc., an NYSE-listed company. Mr. Catelani has also worked with several early-stage start-ups in a variety of industries, including biotechnology, cleantech and retail, in both advisory and management roles and has served as a contract CFO for a number of established businesses in the biotech field. Mr. Catelani began his professional career at Ernst & Young and is a CPA (Inactive). He received his BS degree in business administration, with a concentration in accountancy from Sacramento State University and earned his MBA from the University of California, Davis.

Dr. Garzone is a senior pharmaceutical executive with over 25 years of diverse experience in the industry and is recognized for her strategic, scientific, clinical and regulatory leadership in drug development. Prior to joining Anixa, Dr. Garzone held executive roles in clinical development with several companies, including Calibr, a division of the Scripps Research Institute, and Pfizer. She previously held positions of increasing responsibility at companies such as Elan Pharmaceuticals and Genetics Institute, starting her industry career at Genentech. Prior to her industry experience, she was an Assistant Professor, Pharmacy and Therapeutics at the University of Pittsburgh School of Pharmacy. She earned a B.S. degree in Pharmacy from Purdue University and an M.S. in Pharmacy Practice from the University of Pittsburgh. She received her Ph.D. in Clinical Science from the University of Pittsburgh.

Dr. Kumar has been an investor, founder, director and CEO of several technology enterprises, both public and private. As CEO, he took CombiMatrix Corporation public and ran it for a decade while listed on the NASDAQ Global Market. He has worked in venture capital with OAK Investment Partners, and has been an advisor to investment funds, venture capital firms, and Fortune 500 companies. He was on the Board of Directors of Acacia Research Corporation from 2002-2008. Dr. Kumar is currently Chairman and CEO of Anixa Biosciences and he sits on the Board of other public and private companies. He has served on the Board of the American Cancer Society since 2016. He received his AB in Chemistry from Occidental College. After graduate studies at Stanford University and Caltech, he received his Ph.D. from Caltech and followed that with a post-doctoral fellowship at Harvard.

Mr. Titterton previously served as a Director from August 2010 through August 2016, the last four years of which as Chairman of the Board. He also served as a Director from July 1999 to January 2003. Mr. Titterton's background is in high technology with an emphasis on health care. He is currently the Chairman of the Board of NYMED, Inc., a diversified health services company. Mr. Titterton founded MedE America, Inc. in 1986 and was Chief Executive Officer of Management and Planning Services, Inc. from 1978 to 1986. He holds an MBA from the State University of New York at Albany, and a BA degree from Cornell University.

Dr. Baskies, former Chairman of the national Board of Directors of the American Cancer Society, is a fellowship trained surgical oncologist with special interests in breast cancer, thyroid cancer, and melanoma. He received his Bachelor of Arts degree summa cum laude and was a member of Phi Beta Kappa at Boston University, graduated from the Boston University School of Medicine, completed his surgical residency at Boston Medical Center, and received a fellowship in surgical oncology at the National Cancer Institute.

Emily Gottschalk is an experienced marketer with over 30 years of developing products for the consumer marketplace. She is the founder and CEO of The Garr Group, Inc, a diverse entertainment and new product development company that sells entertainment and general merchandise to the mass, specialty and on-line market. Mass retail customers include Walmart, Sam’s, Walgreens, Target, and others. Past partners include AARP, Intel, Walmart, Disney, Fox, Kellogg’s, Kraft and MLB. TGG, Inc identifies “white space” opportunities in the marketplace and defines and develops products that uniquely touch consumers’ lives. TGG is equally focused on brick and mortar, on-line and emerging distribution channels. Previously, she was Marketing Director of Zany Brainy, a children’s educational toy store that she helped launch. Since 1997, Ms. Gottschalk’s companies have produced over 150 million CD’s/DVD’s to the US retail market, developed a proprietary Android tablet called “RealPad, by AARP” with Intel and has created private label brands across the home, sporting goods and electronics market. She is a graduate of Cornell University’s School of Hotel Administration and serves on the board of Anixa Biosciences, a publicly traded biotechnology company. She is co-founder of the Mildred M. Soefer Foundation offering philanthropic support to Jewish causes and sick children, Entrepreneur in Residence for Cornell University and a strategic, marketing consultant to Jewish Federation of Southern NJ.